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following market authorization of the 13-valent pneumococcal conjugate vaccine 
(PCV13) for adults might be considered. Thus, this study analyzes potential cost-
effectiveness of an adult vaccination with PCV13 from the point of view of the German 
social health insurance. METHODS: In a cross-sectional steady state Markov model, 
efﬁ cacies of the vaccines on invasive pneumococcal diseases (IPD), and community-
acquired pneumonia (CAP, treated in either a hospital or a nonhospital setting) were 
calculated. a steady state is deﬁ ned as a setting in which the whole population (includ-
ing new entrants) is vaccinated as recommended. The modeling of PPV23 and PCV13 
distinguished between risk groups and both vaccines were compared to non-vaccina-
tion. Data on PCV13 were derived from published results on the 7-valent pneumococ-
cal conjugate vaccine (PCV7). The effectiveness of individual pneumococcal 
vaccination of adults was adjusted for expected herd immunity effects of a pediatric 
vaccination with PCV. Utilization of health care services and unit costs were taken 
from publicly accessible data bases. RESULTS: Compared to PPV23, PCV13 revealed 
the potential to avoid a greater number of yearly cases and deaths due to IPD and 
CAP in Germany. For PCV13 it can be expected that monetary savings, resulting e.g. 
from less hospitalization, compensate the costs of the vaccination program. The 
preliminary version of the model concludes that the cost-beneﬁ t ratio is 1.16, i. e. c1 
spend on vaccination saves c1.16 treatment cost. CONCLUSIONS: Our model shows 
that the health economic beneﬁ t of an immunization of adults with PCV13 can be 
expected to be higher than that of PPV23.
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OBJECTIVES: To examine the health and economic impact of PHiD-CV in the public 
sector of Hong Kong compared to no vaccination. METHODS: A Markov analytical 
model modiﬁ ed from the recent Cost-effectiveness Cohort Model for Synﬂ orix (COSY 
Model by HE-group, GCRD, GSK bio, Wavre, Belgium, 2010) was used for the 
analysis of the outcomes of vaccination. The cohort model simulates in a birth cohort 
of 82,100 newborns the disease process of invasive disease (ID) (meningitis and 
bacteremia), community acquired pneumonia (CAP), and acute otitis media (AOM) 
over life-time caused by S pneumoniae and Non-typeable H inﬂ uenzae (NTHi) within 
‘monthly’ cycles. Superimposed on the disease process is integrated in the model its 
disease management expressed in hospitalization rates, medical visits, and speciﬁ c 
interventions such as myringotomies. The epidemiology and disease management is 
Hong Kong speciﬁ c. The study was performed from a health care payer’s perspective. 
RESULTS: The study shows for a 4-dose regimen of PHiD-CV compared to no vac-
cination over a period of 100 years: a gain of 234 quality-adjusted-life-years (QALY); 
an avoidance of 16 cases of IPD, 873 cases of pneumonia, 26,746 cases of AOM and 
25,885 sequelae. Using a 5% discount for cost and beneﬁ ts, cost/QALY gained was 
estimated to be HKD261,492. CONCLUSIONS: With GDP per capita of Hong Kong 
being HKD233,060 in 2009, our study results suggest PHiD-CV vaccination is cost-
effective in providing protection to the people of Hong Kong based on the WHO 
recommended thresholds for cost-effectiveness.
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OBJECTIVES: To evaluate cost-effectiveness of routine pneumococcal vaccination 
with 10-valent pneumococcal non-typeable Haemophilus inﬂ uenzae protein-D vaccine 
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and 
no vaccination. METHODS: A Markov cohort model with a 100-year time horizon 
was developed to project the impact of vaccination on the incidence of pneumococcal 
and non-typeable Haemophilus Inﬂ uenzae (NTHi) infections in children and adults. 
Data Sources: Czech Republic-speciﬁ c epidemiological and demographic data and data 
from other country sources. Base-case assumptions include estimates of pneumococcal 
and NTHi infection rates as well as vaccine efﬁ cacy based on published literature. 
Model inputs: payer perspective, 80% vaccine coverage, no herd protection and a (3 
+ 1) vaccination schedule. One-way sensitivity analyses performed to assess the impact 
of changes in key model assumptions. RESULTS: PHiD-CV and PCV-13 are projected 
to prevent more cases of invasive disease (89 and 92 respectively) and pneumonia 
hospitalizations (738 and 760 respectively) compared with no vaccination. PHiD-CV 
and PCV-13 are projected to prevent additional GPP/ENT visits due to acute otitis 
media (AOM) (7851 and 3838 respectively) compared with no vaccination strategy. 
The total number of cases of invasive disease was comparable for both vaccines but 
PHiD-CV is estimated to prevent more than 14 000 cases of AOM in comparison 
with PCV-13. Vaccinating a birth cohort with PHiD-CV is expected to generate 75.5 
more QALYs and 5.9 LYG compared to PCV-13. Under vaccine price parity assump-
tions, estimated total savings for health care system are 10.2 mil CZK or 395.6 k EUR 
for PHiD-CV compared to PCV-13 respectively. Sensitivity analyses indicate that 
AOM efﬁ cacy and incidence of AOM related GPP/ENT visits have biggest impact on 
results. CONCLUSIONS: Overall, PHiD-CV is expected to have better quality of life 
impact than PCV-13. Under price parity assumptions, PHiD-CV dominates PCV-13 
because it also has a larger cost offsets.
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OBJECTIVES: In contrast to commonly used discrete-time Markov models, we devel-
oped a more realistic continuous-time multi-stage Markov model to evaluate long-term 
clinical and economic outcomes of raltegravir in treatment naïve HIV-1 patients. 
METHODS: The multi-stage cost-effectiveness model incorporating 3 lines of therapy 
was developed using differential equations and was solved in Mathematica® 6.0. The 
analysis was conducted from the perspective of the National payer in Portugal. a 
typical patient enters the model in a given health state, transitions to another health 
state, can develop acquired immunodeﬁ ciency syndrome (AIDS)/ coronary heart 
disease (CHD)/other adverse events or die. Eighteen health states were deﬁ ned based 
on CD4 and HIV RNA levels. We used the maximum likelihood method to estimate 
matrices of instantaneous transition rates corresponding to the efﬁ cacy of the included 
therapies. Six multi-stage treatment strategies depicting clinical practice in Portugal 
were evaluated. The model outputs included projected number of AIDS and CHD 
events, life expectancy and incremental cost-effectiveness ratios (ICER). The model 
was evaluated for internal and external validity and extensive sensitivity analyses were 
conducted. RESULTS: The predicted prevalence of patients in different health states 
over time provided a good ﬁ t to the clinical trial data. Strategies where raltegravir was 
included in the initiating therapy followed by an NNRTI or PI based regimen against 
efavirenz or PI based initiating therapies followed by raltegravir resulted in longer 
undiscounted life expectancy [20.07 Yrs. vs. 18.88 Yrs] and demonstrated cost-
effectiveness [ICERs: c1,078–c33,406/QALY]. CONCLUSIONS: Continuous-time 
Markov modeling based on transition matrices estimated using robust statistical 
methodology is a more realistic and sound approach. Results suggest initiating therapy 
on raltegravir generated lower costs and higher survival versus saving the drug for 
later lines of therapy in Portugal.
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OBJECTIVES: To assess clinical efﬁ cacy and economic effectiveness of Azithromycin 
compared with other antibiotics for community-acquired pneumonia (CAP) and sinus-
itis treatment. METHODS: Decision tree was used to calculate costs of antibiotic 
treatment. The chance nodes included treatment failures and introduction of second-
line therapy or hospitalization. Transition probabilities were obtained from clinical 
trials. Preferred antibiotics for comparison with azithromycin(extended release, 2.0 
g.) and for second-line treatment were chosen by experts in a survey. Medical care 
costs were derived from Moscow mandatory medical insurance system. Costs of the 
medications were obtained from consumer prices database. Sensitivity analysis was 
carried out. RESULTS: Clinical efﬁ cacy was equal. Costs of CAP treatment were 4390 
rub (142.14$) for Amoxycillin and clavulanic acid, 5386 Rub ($174.39) for Cefurox-
ime axetil and 4053 Rub ($131.23) for Azithromycin. Costs of sinusitis treatment 
were 3637(117.76), 3728 (120.71) and 3570 rub ($115,59) for Amoxycillin and 
clavulanic acid, Cefuroxime axetil and Azithromycin respectively. CONCLUSIONS: 
Azithromycin is more efﬁ cient option for CAP and sinusitis treatment than Cefuroxime 
axetil and Amoxycillin and clavulanic acid in Russia.
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OBJECTIVES: To simulate the potential beneﬁ ts of implementing infant vaccination 
with the 10-valent pneumococcal & non-typeable Haemophilus inﬂ uenzae (NTHi)-
protein D conjugate vaccine (PHiD-CV) or the 13-valent pneumococcal conjugate 
vaccine (PCV13) in Latin American countries. METHODS: Vaccine impact was 
assessed using a Markov cohort model for Mexico, Brazil, Chile, and Colombia. The 
model simulates the burden of pneumococcal- and NTHi-related diseases (Invasive 
Disease (ID), Community Acquired Pneumonia (CAP) and Acute Otitis Media (AOM)) 
in a birth cohort followed over a lifetime. Epidemiology, disease management and 
costs are country-speciﬁ c. Vaccination schemes (3 + 1) at 90% coverage & price parity 
were compared to no intervention. Future QALYs and costs discounted at 3.5%, using 
the health care payer perspective are presented. RESULTS: Mortality impact on ID 
and CAP for the two vaccines is projected to be comparable under base-case conditions 
which include minimum assumptions of NTHi infection rates. Vaccines are predicted 
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to reduce 12.8 to 39.0 deaths (PCV13) and 12.4 to 37.3 deaths (PHiD-CV) per 
100,000 vaccinated children. The model predicts that PHiD-CV will prevent 93 to 
494 additional Myringotomies and 651 to 8,314 additional AOM cases per 100,000 
vaccinated children, when compared with PCV13. Medical costs averted are estimated 
similar for ID and CAP. The model predicts that PHiD-CV will prevent 48 to 116% 
more AOM associated costs to the health care system over lifetime than PCV13. In 
the scenarios analyzed, both vaccines are cost-effective but PHiD-CV generates more 
QALYs gains (range 0.04%–14.5%) and is cost saving (range 1.88–12.54%) com-
pared to PCV13. CONCLUSIONS: The model shows both vaccines would signiﬁ -
cantly reduce the clinical & economic burden of Pneumococcal disease and are 
cost-effective for Latin American countries. Nevertheless, due to its greater impact on 
AOM-related cases and costs, PHiD-CV would generate more QALY gains and is 
cost-saving to the health care system compared to PCV13.
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OBJECTIVES: To estimate the cost-effectiveness of the recommended US pediatric 
vaccination schedule from a public health perspective. METHODS: An Excel-based 
cost-effectiveness calculator was constructed for the current pediatric vaccine schedule 
including: diphtheria, tetanus, and pertussis (DTaP), measles, mumps, and rubella 
(MMR), polio, hepatitis A, hepatitis B, haemophilus inﬂ uenza B (Hib), varicella, 
pneumococcal, adolescent meningococcal, inﬂ uenza, human papillomavirus (HPV) 
and rotavirus vaccines. Estimates of the incremental direct medical costs and quality-
adjusted life-years (QALYs) for vaccination versus no vaccination were obtained from 
published literature. Where estimates were not available, a decision tree was con-
structed to model QALYs gained per vaccinated child. The tree includes branches for 
disease incidence pre- and post-vaccine introduction, case-fatality, and permanent, 
serious sequelae. 2008–2009 vaccination coverage and 2009 prices were used to 
estimate vaccine costs. Estimates of lifetime costs and QALYs per vaccinated child, 
discounted at 3% annually, were applied to a US birth cohort, assuming direct effects 
only. Costs are expressed in 2009 US$. Incremental costs and QALYs for individual 
vaccines and the whole schedule were evaluated. The model assessed schedule comple-
tion with single disease vaccines as well as completion with two different pentavalent 
combination vaccines (DTaP, polio, Hib or DTap, polio, hepatitis B) plus single 
disease vaccines. RESULTS: Regardless of how the current pediatric vaccine schedule 
is completed, annual estimated cost savings range between $13.8 billion to $14.3 
billion. DTaP, MMR, polio, Hib and HPV are cost-saving, as are both pentavalent 
vaccines. Other single-disease vaccines add cost but contribute to a total of 1.4M 
QALYs gained per year. CONCLUSIONS: The current US pediatric vaccine schedule 
is estimated to be cost-saving and to provide substantial beneﬁ ts in quality-adjusted 
survival. Use of combination vaccines increases the savings. Neither herd immunity 
nor indirect costs were considered in the model; their inclusion likely would increase 
the estimated cost savings.
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OBJECTIVES: To build a Markov Model that is able to assess the cost-effectiveness 
of adding NAT to the HIV screening strategy at the Brazilian public health system. 
METHODS: A mathematical model was made of the transfusion chain from donors 
to recipients of blood in Brazil. The annual number of avoided HIV transmissions was 
estimated with the window-period incidence model. The natural history of the whole 
blood receptors is described by a Markov model. RESULTS: The incremental cost-
effectiveness ratio—ICER of using NAT instead of ELISA concurrently to another 
ELISA in Brazilian public health system is R$666.493,56 per QALY. The Brazilian 
gross domestic product per capita is R$18.315,50. CONCLUSIONS: The Markov 
Model built is consistent and shows that, despite the narrower window period, at 
current costs, NAT is not cost-effective for HIV screening of donated blood in Brazil. 
Given that the NAT kit is already being produced in-house, the price per kit can be 
adjusted to achieve a better ICER.
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OBJECTIVES: Cost-effectiveness analysis of 4 dose (3 + 1) schedule of the conjugate 
pneumococcal 7-valent vaccine (PCV-7) in infants in the Russian Federation. 
METHODS: Costs associated with Streptococcus pneumoniae infection were calcu-
lated in a modeled cohort of children 0–5 years old with and without vaccination with 
PCV-7. Key parameters in the model included: number of children in the age of 0–5 
years in the country; incidence of diseases caused by S. pneumoniae; the data about 
efﬁ cacy of PVC-7. Costs of vaccination, medical care costs and economic losses of a 
society were taken into account from the societal point of view. Time horizon was 5 
years in the model. RESULTS: Expected cost of vaccination program is c0.469 million. 
Implementation of vaccination with PCV-7 will decrease direct medical costs of care 
for S. pneumoniae infection by c0.516 million. Societal economic losses will decrease 
by c0.975 million. Thus beneﬁ t amount of the PCV-7 vaccination program in a cohort 
of 0–5 years old children will be c1022 million. CONCLUSIONS: Vaccination with 
PCV-7 is an efﬁ cient program in Russia.
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OBJECTIVES: The impact of the HPV(6,11,16,18) vaccine to 12-year-old girls has 
been assessed in Germany by using a static model. However this kind of model cannot 
consider a change in HPV infection rate over time, as observed with high coverage 
rates. Further, this model does not adequately reﬂ ect the recommendation in Germany 
to vaccinate 12 to 17-year-old-girls. a transmission dynamic model was developed for 
the USA to include these features. Our objective was the adaptation of this model to 
Germany to precise the assessment of HPV-vaccination impact. METHODS: In a ﬁ rst 
step we assessed the transferability of the model structure to Germany. In a second 
step we checked input parameters for transferability and identiﬁ ed parameters for 
adaptation. For the identiﬁ ed parameters, we performed a comprehensive literature 
research, supplemented by expert opinions to determine German-speciﬁ c values. The 
model was manually calibrated to ﬁ t observed data in Germany. Calibration param-
eters were number of annual cases of genital warts and cervical cancer as well as 
deaths due to cervical cancer to reﬂ ect the entire time span of occurrence of HPV-
related diseases. RESULTS: The US model structure is also applicable to the German 
context. Components of the model that had to be adapted include demographics (e.g. 
mortality), screening participation, treatment and vaccination strategies, sexual behav-
iour, health utility and economic input parameters. In case no German-speciﬁ c data 
could be found, we used data from the UK and the US. Annual number of incidental 
genital warts was calibrated easily and ﬁ ts well with observed data. However, changes 
in a variety of parameters were necessary for calibration of cervical cancer cases and 
related deaths. CONCLUSIONS: After its successful adaptation, this transmission 
dynamic model can be used for a far more realistic estimation of the clinical and 
economic impact of HPV vaccination in the German context.
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BACKGROUND: Streptococcus pneumonia causes invasive diseases as meningitis and 
bacteremia and non-invasive diseases as pneumonia and acute otitis media (AOM), 
leading to high morbidity and mortality in infants and the elderly worldwide. 
OBJECTIVES: To evaluate the cost-effectiveness of universal infant vaccination with 
13-valent pneumococcal conjugate vaccine (PCV13) compared with PCV10 in 
Taiwan. METHODS: A Markov model was developed to evaluate the potential public 
health and economic impact of PCV13 versus PCV10 when used as routine vaccina-
tion of infants in Taiwan with 4 doses at 2, 4, 6, and 12–15 months of age over a 
10-year time horizon. We included both direct and potential indirect beneﬁ ts of the 
vaccine from societal perspective. Direct effectiveness of PCV13 and PCV10 is esti-
mated from clinical trial data while indirect effectiveness is estimated from U.S. surveil-
lance data. Epidemiology, serotype, medical, and non-medical cost are from Taiwan 
CDC report, and retrospective Taiwan-population-based insurance database. Other 
model parameters were captured by published sources, unpublished data, and assump-
tions made in consultation with clinical experts. Probabilistic sensitivity analyses was 
performed to test the robustness of model assumptions. RESULTS: At vaccination 
price (PCV13 cost used current PCV7 price of NT$3,200 (US$ 98) and PCV10 
NT$2,700 (US$ 83), our model predicts that, compared to PCV10, universal infant 
PCV13 vaccination would avoid 2,215 cases of IPD, approximately 12,473 and 
14,018 cases of hospitalized and non-hospitalized pneumonia, 246,578 cases of AOM; 
prevent 207 deaths from IPD and 85 deaths from hospitalized pneumonia; resulting 
in 4,596 life-years saved, and 3,359 QALYs gained. Comparing PCV13 to PCV10 
results in NT$ 187,462 (US$ 5,768) per life-year saved and cost of NT$ 253,307 (US$ 
7,794) per QALY gained from the societal perspective. CONCLUSIONS: Universal 
pediatric PCV13 vaccination in Taiwan is estimated to reduce the burden of pneumo-
coccal disease and expected to be cost-effective from the societal perspective compared 
with PCV10.
